Haemalogix Raises $10 Million To Advance Multiple Myeloma Treatments
09/08/21, 9:05 PM
Location
sydneyMoney raised
$10 million
HaemaLogiX Pty Ltd, a clinical stage biotech company developing novel immuno-oncology and immune therapies for patients with blood cancers, is pleased to both announce the close of a fully subscribed $10 million placement to sophisticated investors and welcomes Platinum Asset Management as core new institutional investor within its Platinum International Health Care Fund.
Company Info
Location
sydney, new south wales, australia
Additional Info
Founded in 2014, HaemaLogiX Pty Ltd is a clinical stage biotech developing novel immuno-oncology and immune therapies for patients with blood cancers. The Company is focused on the development and commercialisation of monoclonal antibodies (Mab) for the potential treatment of multiple myeloma and potentially other blood cancers.
We have identified and characterised two novel drug targets, Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA), on the surface of human blood cancers and autoimmune cells. These targets are highly specific to the cancer cells identified in blood cancers such as multiple myeloma, some lymphomas and Waldenstrom's macroglobulinemia.